ALGS Aligos Therapeutics, Inc. - Common stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$5.54
· of 52w range
· above low
· to high
$3.9852w low
$13.6952w high
Market Cap (MRQ)
$35M
P/E (TTM)
-4.8
EPS (TTM)
$-1.16
Revenue (TTM)
$4M
your badges
52W Range
$4–$14
Analyst Rating
BUY
Price Target
$52
P/E
-4.8
ROE
-113.6%
Net Profit Margin
-2031.1%
Your badge strip is empty — pin a metric anywhere on this page.
ALGS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$5.54
Market Cap (MRQ)
$35M
P/E (TTM)
-4.8
EPS (TTM)
$-1.16
Revenue (TTM)
$4M
ROE (TTM)
-113.6%
52W Range
$4–$14
ALGS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Aug. 19, 2024 | 1-for-25 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$2M2020-12-31 → 2025-12-31
EPS$-2.452022-12-31 → 2025-12-31
Free Cash Flow·2020-12-31 → 2024-12-31
Net margin-2031.1%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ALGS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -4.85Y avg ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 9.25Y avg ≈90.1 | ≈90.1 | · | · | |
| P/B (MRQ) | 1.15Y avg ≈17.5 | ≈17.5 | · | · | |
| Price / Cash Flow | -0.45Y avg ≈-28.2 | ≈-28.2 | · | · | |
| Price / Tangible Book | 0.65Y avg ≈23.3 | ≈23.3 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ALGS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -2112.1%5Y avg ≈-2639.1% | ≈-2639.1% | -639.7% | Weak | |
| EBITDA Margin | -4024.9%5Y avg ≈-2639.1% | ≈-2639.1% | -639.7% | Weak | |
| Pretax Margin (TTM) | -1945.1%5Y avg ≈-2040.1% | ≈-2040.1% | · | · | |
| Net Profit Margin (TTM) | -2031.1%5Y avg ≈-2052.2% | ≈-2052.2% | -235.8% | Weak | |
| ROA (TTM) | -75.6%5Y avg ≈-61.8% | ≈-61.8% | -16.9% | Below avg | |
| ROE (TTM) | -113.6%5Y avg ≈-308.4% | ≈-308.4% | -14.0% | Below avg | |
| ROIC | -166.5%5Y avg ≈-23.6% | ≈-23.6% | -60.4% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ALGS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 2.25Y avg ≈4.4 | ≈4.4 | 1.9 | Strong liquidity | |
| Quick Ratio (MRQ) | 2.15Y avg ≈4.1 | ≈4.1 | 0.9 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ALGS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -39.5% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ALGS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.0 | ≈0.0 | 0.0 | In line | |
| Revenue / Employee | ≈$26.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
15.7%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 4, 2026 | $-0.14 | $-1.09 | 87.2% |
| March 31, 2026 | $-2.21 | $-2.27 | 2.5% | |
| Dec. 31, 2025 | $-1.91 | $-1.89 | -1.1% | |
| Sept. 30, 2025 | $-3.04 | $-1.94 | -56.9% | |
| June 30, 2025 | $-1.53 | $-2.41 | 36.5% | |
| March 31, 2025 | $-2.11 | $-2.85 | 26.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $2M | $4M | $6M | $0 | $0 | $0 | |
| R&D Expense | $69M | $70M | $73M | $85M | $104M | $80M | |
| SG&A Expense | $21M | $23M | $31M | $26M | $29M | $18M | |
| Operating Expenses | $90M | $93M | $104M | $111M | $133M | $98M | |
| Operating Income | $-88M | $-89M | $-88M | $-98M | $-128M | $-98M | |
| Pretax Income | $-24M | $-131M | $-87M | $-96M | $-128M | $-108M | |
| Income Tax | $314.0K | $331.0K | $795.0K | $106.0K | $143.0K | $161.0K | |
| Net Income | $-24M | $-131M | $-88M | $-96M | $-128M | $-109M | |
| EPS (Basic) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | · | · | |
| EPS (Diluted) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | · | · | |
| Shares (Basic) | 9,884,955 | 6,264,612 | 2,563,470 | 42,695,227 | · | · | |
| Shares (Diluted) | 9,884,955 | 6,264,612 | 2,563,470 | 42,695,227 | · | · | |
| EBITDA | $-88M | $-89M | $-88M | $-98M | $-128M | $-98M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $37M | $136M | $81M | $187M | $220M | |
| Short-term Investments | $60M | $20M | · | $44M | $4M | $23M | |
| Other Current Assets | $5M | $5M | $5M | $8M | $14M | $6M | |
| Current Assets | $83M | $62M | $141M | $134M | $204M | $250M | |
| PP&E (Net) | $2M | $2M | $3M | $5M | $6M | $8M | |
| PP&E (Gross) | $15M | $14M | $14M | $14M | $13M | $12M | |
| Accum. Depreciation | $13M | $12M | $11M | $10M | $7M | $4M | |
| Other Non-current Assets | $715.0K | $627.0K | $625.0K | $634.0K | $866.0K | $377.0K | |
| Total Assets | $89M | $70M | $152M | $147M | $235M | $265M | |
| Accounts Payable | $4M | $3M | $3M | $5M | $3M | $3M | |
| Accrued Liabilities | $14M | $16M | $17M | $16M | $25M | $17M | |
| Current Liabilities | $21M | $22M | $24M | $33M | $39M | $30M | |
| Capital Leases | $2M | $5M | $8M | $9M | $11M | $10M | |
| Other Non-current Liabilities | · | · | · | · | $133.0K | $379.0K | |
| Total Liabilities | $35M | $99M | $59M | $43M | $51M | $45M | |
| Common Stock | $9.0K | $8.0K | $7.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-642M | $-618M | $-487M | $-399M | $-303M | $-175M | |
| AOCI | $468.0K | $451.0K | $545.0K | $401.0K | $452.0K | $-188.0K | |
| Stockholders' Equity | $54M | $-29M | $92M | $104M | $185M | $220M | |
| Liabilities + Equity | $89M | $70M | $152M | $147M | $235M | $265M | |
| Shares Outstanding | 6,178,230 | 3,864,436 | 3,003,855 | 42,922,980 | 42,690,229 | 38,120,606 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $8M | $13M | $15M | $13M | $3M | |
| Deferred Tax | · | $0 | $0 | $0 | $0 | $0 | |
| Operating Cash Flow | $-83M | $-81M | $-79M | $-79M | $-116M | $-74M | |
| CapEx | · | $130.0K | $19.0K | $943.0K | $892.0K | $2M | |
| Investing Cash Flow | $-38M | $-18M | $45M | $-26M | $3M | $33M | |
| Stock Issued | · | · | $23.0K | · | · | · | |
| Financing Cash Flow | $102M | $355.0K | $88M | $164.0K | $79M | $192M | |
| Taxes Paid | $315.0K | · | · | · | · | · | |
| Free Cash Flow | · | $-81M | $-79M | $-80M | $-117M | $-76M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -4024.9% | -2469.0% | -1423.5% | · | · | · | |
| Net Margin | -1106.7% | -3633.7% | -1416.2% | · | · | · | |
| Pretax Margin | -1092.4% | -3624.5% | -1403.4% | · | · | · | |
| EBITDA Margin | -4024.9% | -2469.0% | -1423.5% | · | · | · | |
| ROA | -30.5% | -118.4% | -58.8% | -50.3% | -51.3% | -52.7% | |
| ROE | -31.1% | -1242.4% | -119.4% | -85.0% | -63.9% | -260.4% | |
| ROIC | -166.5% | 308.5% | -96.6% | -94.0% | -69.5% | -44.5% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.9 | 2.9 | 5.9 | 4.0 | 5.2 | 8.3 | |
| Quick Ratio | 3.7 | 2.6 | 5.7 | 3.8 | 4.9 | 8.0 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.67 | $-7.50 | $1.23 | $2.42 | $4.33 | $6.01 | |
| Revenue / Share | $0.22 | $0.58 | $0.10 | · | · | · | |
| Cash Flow / Share | $-8.35 | $-12.89 | $-1.23 | · | · | · | |
| Cash / Share | $2.96 | $9.57 | $1.81 | $1.90 | $4.38 | $6.02 | |
| EPS (TTM) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -39.5% | -41.7% | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $4M | $6M | $0 | $0 | $0 | |
| Net Income TTM | $-24M | $-131M | $-88M | $-96M | $-128M | $-109M | |
| Market Cap | $58M | $154M | $1.25B | $1.02B | $12.67B | $25.30B | |
| P/E | -3.8 | -1.9 | -0.5 | -10.6 | · | · | |
| P/S | 26.3 | 42.6 | 201.4 | · | · | · | |
| P/B | 1.1 | -5.3 | 13.5 | 9.8 | 68.6 | 115.0 | |
| P / Tangible Book | 1.1 | · | 13.5 | 9.8 | 68.6 | 115.0 | |
| P / Cash Flow | -0.7 | -1.9 | -15.8 | -12.9 | -109.5 | -340.7 | |
| P / FCF | · | -1.9 | -15.8 | -12.7 | -108.7 | -331.5 | |
| Earnings Yield | -26.3% | -52.6% | -206.0% | -9.4% | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $3M | $169.0K | $741.0K | $965.0K | $311.0K | $606.0K | $1M | $1M | $694.0K | $672.0K | $1M | $4M | $140.0K | · | $0 | |
| R&D Expense | $24M | $23M | $17M | $24M | $14M | $15M | $16M | $17M | $21M | $16M | $22M | $16M | $17M | $18M | $19M | $18M | |
| SG&A Expense | $6M | $6M | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $7M | $6M | $6M | $9M | $9M | $7M | $5M | |
| Operating Expenses | $30M | $30M | $22M | $29M | $20M | $20M | $21M | $21M | $27M | $23M | $29M | $22M | $26M | $27M | $26M | $23M | |
| Operating Income | $-2M | $-27M | $-22M | $-28M | $-19M | $-19M | $-21M | $-20M | $-26M | $-22M | $-26M | $-19M | $-19M | $-24M | $-23M | $-19M | |
| Pretax Income | $1M | $-23M | $-20M | $-31M | $-16M | $43M | $-82M | $-19M | $5M | $-35M | $-28M | $-18M | $-18M | $-23M | $-22M | $-19M | |
| Income Tax | $3M | $317.0K | $30.0K | $56.0K | $185.0K | $43.0K | $27.0K | $91.0K | $189.0K | $24.0K | $-30.0K | $29.0K | $757.0K | $39.0K | $49.0K | $-43.0K | |
| Net Income | $-2M | $-23M | $-20M | $-32M | $-16M | $43M | $-82M | $-19M | $5M | $-35M | $-28M | $-18M | $-19M | $-23M | $-22M | $-19M | |
| EPS (Basic) | $-0.14 | $-2.21 | $-3.00 | $-3.04 | $-1.53 | $5.12 | $-13.10 | $-3.07 | $0.81 | $-5.58 | $-22.87 | $-10.37 | $-0.43 | $-0.53 | $-0.50 | $-0.44 | |
| EPS (Diluted) | $-0.14 | $-2.21 | $4.23 | $-3.04 | $-1.53 | $-2.11 | $-13.10 | $-3.07 | $0.81 | $-5.58 | $-22.87 | $-10.37 | $-0.43 | $-0.53 | $-0.50 | $-0.44 | |
| Shares (Basic) | 10,430,808 | 10,402,967 | · | 10,369,535 | 10,351,120 | 8,408,481 | · | 6,272,291 | 6,257,713 | 6,246,113 | · | 1,739,847 | 43,215,478 | 42,910,065 | · | 42,761,928 | |
| Shares (Diluted) | 10,430,808 | 10,402,967 | · | 10,369,535 | 10,351,120 | 8,709,693 | · | 6,272,291 | 6,265,853 | 6,246,113 | · | 1,739,847 | 43,215,478 | 42,910,065 | · | 42,761,928 | |
| EBITDA | · | $-27M | · | $-28M | $-19M | $-19M | · | $-20M | $-26M | $-22M | · | $-19M | $-19M | $-24M | · | $-19M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30M | $30M | $18M | $42M | $19M | $74M | $37M | $35M | $45M | $24M | $136M | $70M | $91M | $79M | $81M | $86M | |
| Short-term Investments | $0 | $25M | $60M | $57M | $104M | $64M | $20M | $40M | $49M | $89M | · | · | $10.0K | $25M | $44M | $56M | |
| Receivables | $28M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $4M | $5M | $5M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | $6M | $8M | $8M | |
| Current Assets | $62M | $60M | $83M | $103M | $128M | $143M | $62M | $80M | $100M | $118M | $141M | $75M | $94M | $109M | $134M | $150M | |
| PP&E (Net) | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $5M | |
| PP&E (Gross) | $15M | $15M | $15M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | |
| Accum. Depreciation | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | $10M | $10M | $9M | |
| Other Non-current Assets | $759.0K | $759.0K | $715.0K | $713.0K | $640.0K | $632.0K | $627.0K | $635.0K | $631.0K | $625.0K | $625.0K | $623.0K | $624.0K | $632.0K | $634.0K | $653.0K | |
| Total Assets | $66M | $65M | $89M | $110M | $135M | $151M | $70M | $88M | $109M | $128M | $152M | $86M | $106M | $122M | $147M | $164M | |
| Accounts Payable | $6M | $8M | $4M | $5M | $4M | $4M | $3M | $3M | $7M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | |
| Accrued Liabilities | $19M | $12M | $14M | $14M | $12M | $11M | $16M | $14M | $12M | $12M | $17M | $12M | $14M | $15M | $16M | $14M | |
| Current Liabilities | $28M | $23M | $21M | $22M | $20M | $19M | $22M | $21M | $24M | $19M | $24M | $22M | $27M | $28M | $33M | $31M | |
| Capital Leases | $288.0K | $659.0K | $2M | $2M | $3M | $4M | $5M | $6M | $6M | $7M | $8M | $8M | $9M | $9M | $9M | $10M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $133.0K | |
| Total Liabilities | $34M | $33M | $35M | $38M | $33M | $34M | $99M | $38M | $42M | $68M | $59M | $31M | $36M | $37M | $43M | $42M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $4.0K | $0 | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-667M | $-665M | $-642M | $-622M | $-591M | $-575M | $-618M | $-536M | $-517M | $-522M | $-487M | $-459M | $-441M | $-422M | $-399M | $-377M | |
| AOCI | $437.0K | $438.0K | $468.0K | $455.0K | $420.0K | $447.0K | $451.0K | $577.0K | $494.0K | $476.0K | $545.0K | $497.0K | $497.0K | $499.0K | $401.0K | $159.0K | |
| Stockholders' Equity | $32M | $32M | $54M | $72M | $102M | $116M | $-29M | $50M | $67M | $60M | $92M | $55M | $70M | $85M | $104M | $122M | |
| Liabilities + Equity | $66M | $65M | $89M | $110M | $135M | $151M | $70M | $88M | $109M | $128M | $152M | $86M | $106M | $122M | $147M | $164M | |
| Shares Outstanding | 6,236,828 | 6,188,186 | 6,178,230 | 6,153,507 | 6,151,274 | 6,114,801 | 3,864,436 | 3,324,780 | 79,785,898 | 75,668,521 | 3,003,855 | 43,502,582 | 43,502,582 | 42,940,089 | 42,922,980 | 42,815,593 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $1M | $959.0K | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $3M | $3M | |
| Operating Cash Flow | $-25M | $-23M | $-22M | $-24M | $-16M | $-21M | $-18M | $-20M | $-19M | $-23M | $-23M | $-20M | $-14M | $-22M | $-17M | $-17M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.0K | $91.0K | $3.0K | |
| Investing Cash Flow | $25M | $35M | $-2M | $48M | $-39M | $-44M | $20M | $10M | $40M | $-89M | $-7.0K | $-9.0K | $25M | $20M | $12M | $32M | |
| Financing Cash Flow | $220.0K | $-62.0K | $123.0K | $-53.0K | $-177.0K | $102M | $97.0K | $-4.0K | $281.0K | $-19.0K | $88M | $-21.0K | $414.0K | $-1.0K | $121.0K | $-19.0K | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-22M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -951.5% | · | -3827.4% | -1924.0% | -6187.5% | · | -1610.5% | -2489.5% | -3176.7% | · | -1757.7% | -445.8% | -17084.3% | · | · | |
| Net Margin | · | -814.1% | · | -4256.0% | -1643.8% | 13854.7% | · | -1540.7% | 477.0% | -5023.5% | · | -1662.8% | -437.6% | -16396.4% | · | · | |
| Pretax Margin | · | -802.9% | · | -4248.4% | -1624.7% | 13868.5% | · | -1533.4% | 494.8% | -5020.0% | · | -1660.1% | -420.0% | -16368.6% | · | · | |
| EBITDA Margin | · | -951.5% | · | -3827.4% | -1924.0% | -6187.5% | · | -1610.5% | -2489.5% | -3176.7% | · | -1757.7% | -445.8% | -17084.3% | · | · | |
| ROA | · | -21.4% | · | -31.8% | -13.0% | 30.9% | · | -22.1% | 4.7% | -27.9% | · | -14.4% | -13.0% | -13.8% | · | -8.7% | |
| ROE | · | -31.1% | · | -51.7% | -18.8% | 48.9% | · | -36.7% | 7.4% | -48.2% | · | -20.4% | -18.2% | -19.3% | · | -11.0% | |
| ROIC | · | -85.9% | · | -39.6% | -18.4% | -16.5% | · | -40.4% | -37.9% | -36.9% | · | -34.8% | -28.6% | -28.3% | · | -15.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 2.6 | · | 4.7 | 6.3 | 7.6 | · | 3.8 | 4.2 | 6.3 | · | 3.3 | 3.5 | 3.9 | · | 4.9 | |
| Quick Ratio | · | 2.4 | · | 4.5 | 6.1 | 7.3 | · | 3.6 | 4.0 | 6.0 | · | 3.1 | 3.3 | 3.7 | · | 4.7 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $5.14 | · | $11.67 | $16.56 | $19.04 | · | $15.07 | $0.84 | $0.79 | · | $1.26 | $1.60 | $1.97 | · | $2.85 | |
| Revenue / Share | · | $0.27 | · | $0.07 | $0.09 | $0.04 | · | $0.20 | $0.01 | $0.00 | · | $0.02 | $0.10 | $0.00 | · | · | |
| Cash Flow / Share | · | $-2.22 | · | · | · | $-2.40 | · | · | · | $-0.15 | · | · | · | $-0.52 | · | · | |
| Cash / Share | · | $4.84 | · | $6.82 | $3.03 | $12.06 | · | $10.63 | $0.56 | $0.32 | · | $1.62 | $2.09 | $1.83 | · | $2.02 | |
| EPS (TTM) | $-1.16 | $-2.55 | · | $-19.78 | $-19.81 | $-17.47 | · | $-30.71 | $-38.01 | $-39.25 | · | $-11.83 | $-1.90 | $-1.94 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $5M | · | $3M | $3M | $3M | · | $4M | $4M | $7M | · | · | · | · | · | · | |
| Net Income TTM | $-76M | $-90M | · | $-86M | $-74M | $-53M | · | $-77M | $-76M | $-100M | · | $-82M | $-82M | $-83M | · | $-112M | |
| Market Cap | · | $46M | · | $60M | $44M | $50M | · | $29M | $698M | $1.85B | · | $812M | $1.06B | $938M | · | $1.18B | |
| P/E | -5.0 | -2.9 | · | -0.5 | -0.4 | -0.5 | · | -0.3 | -0.2 | -0.6 | · | -1.6 | -12.8 | -11.3 | · | · | |
| P/S | 9.6 | 9.8 | · | 23.0 | 14.2 | 15.6 | · | 7.8 | 198.8 | 274.9 | · | · | · | · | · | · | |
| P/B | 1.1 | 1.4 | · | 0.8 | 0.4 | 0.4 | · | 0.6 | 10.4 | 31.0 | · | 14.8 | 15.2 | 11.1 | · | 9.7 | |
| P / Tangible Book | 1.1 | 1.4 | · | 0.8 | 0.4 | 0.4 | · | 0.6 | 10.4 | 31.0 | · | 14.8 | 15.2 | 11.1 | · | 9.7 | |
| P / Cash Flow | · | -2.0 | · | · | · | -2.4 | · | · | · | -81.5 | · | · | · | -41.9 | · | · | |
| Earnings Yield | -20.1% | -34.3% | · | -201.8% | -274.8% | -211.8% | · | -354.6% | -434.4% | -160.2% | · | -63.3% | -7.8% | -8.9% | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $2M | $4M | $6M | $0 | $0 |
| Operating Margin % | -4024.9% | -2469.0% | -1423.5% | · | · |
| Net Income | $-24M | $-131M | $-88M | $-96M | $-128M |
| Diluted EPS | $-2.45 | $-20.94 | $-34.20 | $-2.25 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 3.9 | 2.9 | 5.9 | 4.0 | 5.2 |
| Quick Ratio | 3.7 | 2.6 | 5.7 | 3.8 | 4.9 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | $-81M | $-79M | $-80M | $-117M |
Institutional owners (13F) 34 filers · $15.3M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
34
Value held
$15.3M
New positions
5
Exited positions
9
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (-2 vs prior Q) | 9 (+2 vs prior Q) | 7 (-1 vs prior Q) | 7 (-2 vs prior Q) | -483K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Deep Track Capital, LP | $2,562,515 | 444,110 | 16.70% | Shares |
| Alyeska Investment Group, L.P. | $2,377,240 | 412,000 | 15.49% | Shares |
| Sio Capital Management, LLC | $1,888,157 | 327,237 | 12.30% | Shares |
| VANGUARD GROUP INC | $1,867,682 | 200,395 | 12.17% | Shares |
| MARSHALL WACE, LLP | $1,422,761 | 246,579 | 9.27% | Shares |
| Woodline Partners LP | $1,023,379 | 177,362 | 6.67% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,012,883 | 175,543 | 6.60% | Shares |
| BAKER BROS. ADVISORS LP | $479,227 | 83,055 | 3.12% | Shares |
| HHLR ADVISORS, LTD. | $439,945 | 76,247 | 2.87% | Shares |
| D. E. Shaw & Co., Inc. | $383,491 | 66,463 | 2.50% | Shares |
| UBS Group AG | $346,119 | 59,986 | 2.26% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $272,319 | 47,173 | 1.77% | Shares |
| JANE STREET GROUP, LLC | $186,959 | 32,402 | 1.22% | Shares |
| BlackRock, Inc. | $174,785 | 30,292 | 1.14% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $165,091 | 28,612 | 1.08% | Shares |
| AlphaQuest LLC | $129,324 | 13,876 | 0.84% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $121,424 | 21,044 | 0.79% | Shares |
| TWO SIGMA ADVISERS, LP | $121,160 | 13,000 | 0.79% | Shares |
| Verition Fund Management LLC | $108,978 | 18,887 | 0.71% | Shares |
| Trexquant Investment LP | $71,196 | 12,339 | 0.46% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $62,316 | 10,800 | 0.41% | Shares |
| Rockefeller Capital Management L.P. | $57,700 | 10,000 | 0.38% | Shares |
| Federation des caisses Desjardins du Quebec | $26,831 | 4,650 | 0.17% | Shares |
| Golden State Wealth Management, LLC | $15,429 | 2,674 | 0.10% | Shares |
| ROYAL BANK OF CANADA | $12,000 | 2,125 | 0.08% | Shares |
| CITIGROUP INC | $10,432 | 1,808 | 0.07% | Shares |
| Tower Research Capital LLC (TRC) | $2,071 | 359 | 0.01% | Shares |
| JPMORGAN CHASE & CO | $1,868 | 344 | 0.01% | Shares |
| MORGAN STANLEY | $1,177 | 204 | 0.01% | Shares |
| SBI Securities Co., Ltd. | $727 | 126 | 0.00% | Shares |
| WELLS FARGO & COMPANY/MN | $577 | 100 | 0.00% | Shares |
| FMR LLC | $58 | 10 | 0.00% | Shares |
| ELEVATION WEALTH PARTNERS, LLC | $24 | 4 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $17 | 3 | 0.00% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Lawrence M. Blatt ×2 filings | June 24, 2026 | 5.60% | Initial filing | Passive investment | SEC |
| Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP, L.P., Versant Vantage I GP-GP, LLC ×4 filings | Feb. 8, 2024 | · | Initial filing | · | SEC |
| Lawrence M. Blatt, Ph.D. | Nov. 6, 2023 | · | Initial filing | Passive investment | SEC |
| Novo Holdings A/S ×3 filings | Jan. 31, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 18 insiders · 8 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lawrence M. Blatt, Ph.D. | President and CEO | March 9, 2026 A | 1,847,575 | 0 | 0 | $0 |
| Lesley Ann Calhoun | Chief Operating Officer and Chief Financial Officer | March 9, 2026 A | · | 0 | 0 | $0 |
| Leonid Beigelman | President | March 15, 2023 A | 18,355 | 0 | 0 | $0 |
| Nikhil Aneja | Principal Accounting Officer | March 9, 2026 A | · | 0 | 0 | $0 |
| Julian A. Symons | Executive Vice President, Chief Scientific Officer | March 9, 2026 A | 394,064 | 0 | 0 | $0 |
| Hardean Achneck | Chief Medical Officer | Oct. 8, 2024 A | · | 0 | 0 | $0 |
| Matthew W. Mcclure | Chief Medical Officer | March 1, 2024 A | · | 0 | 0 | $0 |
| Lucinda Y. Quan | Executive Vice President, Chief Business Officer and General Counsel | Sept. 8, 2023 A | 9,258 | 0 | 0 | $0 |
| Margarita Chavez | Director | June 25, 2026 A | · | 0 | 0 | $0 |
| Peter Hirth | Director | June 25, 2026 A | · | 0 | 0 | $0 |
| Carole Nuechterlein | Director | June 25, 2026 A | 11,025,941 | 0 | 0 | $0 |
| Bridget A Martell | Director | June 25, 2026 A | · | 0 | 0 | $0 |
| Heather Preston | Director | June 25, 2026 A | · | 0 | 0 | $0 |
| James Paul Scopa | Director | June 25, 2026 A | 183,083 | 0 | 0 | $0 |
| Jack Nielsen | Director | Feb. 28, 2024 A | · | 0 | 0 | $0 |
| Thomas Woiwode | Director | June 23, 2022 A | 4,452 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% owner | Oct. 20, 2020 C | 1,906,191 | 0 | 0 | $0 |
| Novo Holdings A/S | 10% owner | Oct. 20, 2020 C | 2,614,563 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.01% | 16,320 SH | Sept. 11, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.00% | 1,149 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 2,810 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 46,773 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 128,770 SH | Aug. 19, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 1,855 NS | July 31, 2026 | N-PORT |
ALGS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 14 analysts
BUY
Median target
$40.50
+631.0%
3 21.4%
Strong Buy
10 71.4%
Buy
1 7.1%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
8 analysts · 2026-10-02Mean target $52.38 +845.4%
← Below all targets
Current price $5.54
Low$20.00
Mean$52.38
High$175.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026